Abstract
Background Activating the herpesvirus lytic replication cycle presents an opportunity for targeted therapy. We explored the effects of endoplasmic reticulum (ER) stress inducers on Kaposi’s sarcoma herpesvirus (KSHV) lytic activation in primary effusion lymphoma (PEL) cell lines. We included nelfinavir (an HIV-1 protease inhibitor) in our investigations because it has been reported to induce ER stress in various tumor cell lines [1]. Treatment with bortezomib, thapsigargin or nelfinavir resulted in increased expression of ER stress markers such as activating transcription factor 4 (ATF-4) and the spliced form of X-box binding protein 1 (XBP-1(s) (see figure 1). Treatment was also associated with an increase in RNA expression of the KSHV immediate early “replication and transcriptional activator” (RTA) (see figure 2). To determine whether ER stress mediated KSHV lytic reactivation associated with these agents, we prepared doxycycline-activated short hairpin RNA knockdowns of ER stress genes (Grp78 and XBP-1(s)). Treatment of these knockdowns with doxycycline for 72 hours resulted in inhibition of ER stress and inhibition of viral lytic gene expression.
Highlights
Activating the herpesvirus lytic replication cycle presents an opportunity for targeted therapy
We explored the effects of endoplasmic reticulum (ER) stress inducers on Kaposi’s sarcoma herpesvirus (KSHV) lytic activation in primary effusion lymphoma (PEL) cell lines
Thapsigargin or nelfinavir resulted in increased expression of ER stress markers such as activating transcription factor 4 (ATF-4) and the spliced form of X-box binding protein 1 (XBP-1(s)
Summary
ER stress activates lytic gene expression in KSHVassociated tumor cell lines Nene Kalu1*, Courtney Shirley, Richard Ambinder. From 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Bethesda, MD, USA. From 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Bethesda, MD, USA. 7-8 November 2011
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.